Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1967 2
1969 1
1980 1
1982 1
1985 1
1986 2
1987 1
1992 5
1993 3
1994 4
1995 4
1997 2
1998 4
2000 4
2001 3
2002 1
2003 2
2004 2
2005 4
2006 9
2007 7
2008 10
2009 9
2010 6
2011 11
2012 9
2013 10
2014 7
2015 19
2016 10
2017 9
2018 6
2019 19
2020 7
2021 9
2022 12
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
Photocontrollable mononegaviruses.
Tahara M, Takishima Y, Miyamoto S, Nakatsu Y, Someya K, Sato M, Tani K, Takeda M. Tahara M, et al. Among authors: nakatsu y. Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11587-11589. doi: 10.1073/pnas.1906531116. Epub 2019 May 28. Proc Natl Acad Sci U S A. 2019. PMID: 31138700 Free PMC article.
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Yasuda S, et al. N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2. N Engl J Med. 2019. PMID: 31475793 Clinical Trial.
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Naito R, et al. JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561. JAMA Cardiol. 2022. PMID: 35704345 Free PMC article. Clinical Trial.
Roles of peptidyl prolyl isomerase Pin1 in viral propagation.
Kanna M, Nakatsu Y, Yamamotoya T, Encinas J, Ito H, Okabe T, Asano T, Sakaguchi T. Kanna M, et al. Among authors: nakatsu y. Front Cell Dev Biol. 2022 Oct 25;10:1005325. doi: 10.3389/fcell.2022.1005325. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36393854 Free PMC article. Review.
Prolyl isomerase Pin1 in metabolic reprogramming of cancer cells.
Nakatsu Y, Yamamotoya T, Ueda K, Ono H, Inoue MK, Matsunaga Y, Kushiyama A, Sakoda H, Fujishiro M, Matsubara A, Asano T. Nakatsu Y, et al. Cancer Lett. 2020 Feb 1;470:106-114. doi: 10.1016/j.canlet.2019.10.043. Epub 2019 Oct 31. Cancer Lett. 2020. PMID: 31678165 Review.
Development of Pin1 Inhibitors and their Potential as Therapeutic Agents.
Nakatsu Y, Matsunaga Y, Ueda K, Yamamotoya T, Inoue Y, Inoue MK, Mizuno Y, Kushiyama A, Ono H, Fujishiro M, Ito H, Okabe T, Asano T. Nakatsu Y, et al. Curr Med Chem. 2020;27(20):3314-3329. doi: 10.2174/0929867325666181105120911. Curr Med Chem. 2020. PMID: 30394205 Review.
Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H, Nakatsu Y, Kushiyama A, Yamamotoya T, Matsunaga Y, Inoue MK, Fujishiro M, Sakoda H, Ohno H, Yoneda M, Ono H, Asano T. Okubo H, et al. Among authors: nakatsu y. Curr Med Chem. 2018;25(9):984-1001. doi: 10.2174/0929867324666171009121702. Curr Med Chem. 2018. PMID: 28990516 Review.
205 results